Australia markets open in 50 minutes

Prestige BioPharma Limited (950210.KS)

KSE - KSE Delayed price. Currency in KRW
Add to watchlist
8,100.00+10.00 (+0.12%)
At close: 03:30PM KST
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
30/06/2023
30/06/2022
30/06/2021
30/06/2020
Cash flows from operating activities
Net income
-46,029,137
17,569,286
-211,450,137
-7,390,936
-14,996,866
Depreciation & amortisation
-
11,649,790
3,866,586
1,667,282
1,184,944
Stock-based compensation
-
1,943,154
3,773,820
2,954,573
-
Change in working capital
-
-18,722,518
-19,044,278
2,072,726
-3,024,342
Inventory
-
-10,038,122
-24,041,382
-
-
Other working capital
-96,869,790
-125,890,668
-114,019,891
-33,557,839
-31,154,285
Other non-cash items
59,684,300
-12,824,802
-4,733,241
276,288
1,529,086
Net cash provided by operating activities
-50,579,011
-60,273,986
-45,907,256
-15,446,403
-12,420,889
Cash flows from investing activities
Investments in property, plant and equipment
-46,290,779
-65,616,682
-68,112,635
-18,111,436
-18,733,396
Purchases of investments
-
-133,827,100
-25,239,416
-
-
Other investing activities
9,535,184
9,662,183
12,971,968
-2,323,456
859,804
Net cash used for investing activities
-34,111,920
-148,610,252
-184,685,250
-20,912,358
-18,039,290
Net change in cash
-31,591,751
-148,812,582
-238,272,578
417,880,250
35,608,068
Cash at beginning of period
261,000,774
274,722,105
487,841,815
43,495,354
10,175,568
Cash at end of period
229,777,689
125,909,523
249,569,236
461,375,603
45,783,636
Free cash flow
Operating cash flow
-50,579,011
-60,273,986
-45,907,256
-15,446,403
-12,420,889
Capital expenditure
-46,290,779
-65,616,682
-68,112,635
-18,111,436
-18,733,396
Free cash flow
-96,869,790
-125,890,668
-114,019,891
-33,557,839
-31,154,285